Loading...
In addition to Ojemda, an authorized treatment for some childhood brain tumors that are difficult to cure, the planned acquisition would provide Servier with a few investigational medications undergoing human development.
Servier, a French pharmaceutical company, has consented to a multibillion-dollar acquisition that, if finalized, will expand its cancer treatment portfolio.
Servier will pay $21.50 in cash for each share of Day One Biopharmaceuticals as part of the acquisition, which was announced on Friday. That implies a total equity worth of about $2.5 billion and is 68% more than Day One's prior closing share price. The businesses anticipate closing between April and the end of June.
Samuel Blackman, a physician-scientist and seasoned businessman, and Julie Grant, a general partner at the venture capital company Canaan Partners, created Day One in 2018. Its name comes from "the day one talk," in which doctors inform patients and their families of their initial cancer diagnosis and treatment plan. Although Day One has stated that it wants to assist patients of all ages, developing novel or cutting-edge treatments for juvenile cancers has been the company's top priority thus far.
Before going public in the middle of 2021 and raising an additional $160 million, Day One had accumulated $192 million in equity. It entered the market at a time when the coronavirus epidemic was causing a technological bubble to implode. The biotech stock market experienced a historic decline in the ensuing years, forcing many businesses to reduce staff, curtail research, and focus their goals. Day One's shares were still 20% below their initial price before to Friday's announcement.
The sale "represents a unique opportunity to extend the reach" of Day One's science, according to a statement from CEO Jeremy Bender. Bender emphasized how Servier's experience with rare diseases and efforts to advance targeted medicines make it the "ideal home for our portfolio." Tibsovo, Voranigo, and Onivyde are just a few of the cancer medications that Servier currently sells.
Servier reported sales of 6.9 billion euros, or about $7.9 billion, during its fiscal year, which runs from 2024 to 2025. Its oncology division now made up over one-third of the total, up 55% from the previous year. According to the corporation, one of their objectives is for the cancer market to grow to 4 billion euros by 2030.
CEO Jeremy Bender said in a statement that the sale "represents a unique opportunity to extend the reach" of Day One's science. Bender highlighted how Servier is the "ideal home for our portfolio" because to its expertise with uncommon diseases and initiatives to develop targeted medications. Servier presently offers a number of cancer drugs, including Tibsovo, Voranigo, and Onivyde.
During its fiscal year, which spans from 2024 to 2025, Servier reported sales of 6.9 billion euros, or roughly $7.9 billion. Its oncology department now accounted for more than one-third of the total, a 55% increase over the prior year. The company claims that one of its goals is for the cancer market to reach 4 billion euros by 2030.
Cognito's $105 million Series C investment will further their groundbreaking FDA study, broaden clinical neurology collaborations, and extend their work beyond Alzheimer's to Parkinson's disease and other conditions.
